Money still missing as the plan to synthesize a human genome takes another step forward
By Ryan Cross,
Science Magazine
| 05. 08. 2017
Tuesday morning, more than 200 biologists, businesspeople, and ethicists will converge on the New York Genome Center in New York City to jump-start what they hope will be biology’s next blockbuster: Genome Project-write (GP-write), a still-unfunded sequel to the Human Genome Project where instead of reading a human genome, scientists create one from scratch and incorporate it into cells for various research and medical purposes. For example, proponents suggest that they could design a synthetic genome to make human cells resistant to viral infections, radiation, and cancer. Those cells could be used immediately for industrial drug production. With additional genome tinkering to avoid rejection by the immune system, they could be used clinically as a universal stem cell therapy.
The project got off to a bumpy start last year and despite the central rallying cry of a synthetic human genome, many of those attending the conference will bring in different expectations and ambitions. Some resent the unwanted attention and criticism that the project’s public objective has brought, saying it distracts from the goal of improving DNA synthesis technologies, because cheaper...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Eric Schmidt, TIME | 04.16.2024
Imagine a world where everything from plastics to concrete is produced from biomass. Personalized cell and gene therapies prevent pandemics and treat previously incurable genetic diseases. Meat is lab-grown; enhanced nutrient grains are climate-resistant. This is what the future could...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...